Q2 2018 13F Holders as of 6/30/2018
-
Type / Class
-
Equity / Common Shares, without par value
-
Shares outstanding
-
193M
-
Number of holders
-
64
-
Total 13F shares, excl. options
-
20.4M
-
Shares change
-
+3.83M
-
Total reported value, excl. options
-
$149M
-
Value change
-
+$30.1M
-
Put/Call ratio
-
0.38
-
Number of buys
-
44
-
Number of sells
-
-18
-
Price
-
$7.30
Significant Holders of Arbutus Biopharma Corp - Common Shares, without par value (ABUS) as of Q2 2018
80 filings reported holding ABUS - Arbutus Biopharma Corp - Common Shares, without par value as of Q2 2018.
Arbutus Biopharma Corp - Common Shares, without par value (ABUS) has 64 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 20.4M shares
of 193M outstanding shares and own 10.56% of the company stock.
Largest 10 shareholders include RTW INVESTMENTS, LP (5.17M shares), PRIMECAP MANAGEMENT CO/CA/ (4M shares), Foresite Capital Management IV, LLC (2.65M shares), BlackRock Inc. (2.39M shares), BANK OF MONTREAL /CAN/ (945K shares), MORGAN STANLEY (736K shares), STATE STREET CORP (499K shares), D. E. Shaw & Co., Inc. (471K shares), GOLDMAN SACHS GROUP INC (353K shares), and NORTHERN TRUST CORP (296K shares).
This table shows the top 64 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.